Optimized Basement Membrane Extracts for Organoid Growth and Xenograft Models
![](/46/pdcnewsitem/03/22/66/dJjWPV1aWgIb7g3.jpg)
AMSBIO announces the availability of two new formulations of Basement Membrane Extract (BME) known as Cultrex BME 2 (organoid growth matrix) and Cultrex BME 3 (xenograft/tumorgraft matrix).
The new products have been developed to address the heterogeneous nature of tissue and organ micro-environments that not only arise from organ specific stromal cells, growth factors, proteoglycans, and protein composition but also from the stiffness or tensile strength of the BME. Many studies have shown that there is a relationship between abnormal tensile strength and both cancer progression and fibrotic tissues. It is both the chemical and physical properties of the BME that are responsible for the mechanical and biological properties of tissues and organs. It was in light of this heterogeneity that Cultrex BME 2 and Cultrex BME 3 were developed.
BME 2 is based upon a proprietary formulation that is higher in tensile strength than original Matrigel or Cultrex BME. This growth factor reduced product is recommended for organoid growth applications including 3D cell culture from stem cells. By comparison, BME 3 has been developed to be physiologically aligned with the in vivo tumour environment and is recommended for xenografts, tumorgrafts and other in vivo applications.
Basement membranes are continuous sheets of specialized extracellular matrix that form an interface between endothelial, epithelial, muscle, or neuronal cells and their adjacent stroma. Basement membranes are degraded and regenerated during development and wound repair. They not only support cells and cell layers, but they also play an essential role in tissue organization that affects cell adhesion, migration, proliferation, and differentiation. Basement membranes provide major barriers to invasion by metastatic tumour cells. Cultrex BME is a soluble form of basement membrane purified from Engelbreth-Holm-Swarm (EHS) tumours. The extract gels at 37 °C to form a reconstituted basement membrane. The major components of BME include laminin, collagen IV, entactin, and heparin sulphate proteoglycan. BME can be used for growth promotion or for the differentiation of precursor cells, under a variety of cell culture conditions, involving primary epithelial, endothelial and smooth muscle cells. BME has also been employed in cell attachment, neurite outgrowth, angiogenesis assays, in vitro cell invasion and in vivo tumorigenicity assays.
For further information on Cultrex BME 2 and Cultrex BME 3 please visit http://www.amsbio.com/
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance